Related Experiment Video
Updated: Aug 8, 2026
Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in
T I G van der Spoel1, W A Gathier1, S Koudstaal1
1Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Rm E03.511, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Insights
Mesenchymal stem cells (MSC) improved systolic function in pigs with chronic myocardial infarction (MI). Bone marrow-derived mononuclear cells (BMMNC) did not show significant improvement, indicating MSCs are more effective for cardiac repair.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Stem Cell Therapy
Background:
- Chronic myocardial infarction (MI) presents a significant therapeutic challenge.
- Optimal cell types for cardiac cell therapy remain under investigation.
- Autologous bone marrow-derived mononuclear cells (BMMNC) and mesenchymal stem cells (MSC) are potential candidates.
Purpose of the Study:
- To compare the therapeutic efficacy of MSCs versus BMMNCs in a chronic MI model.
- To evaluate the effect of repetitive, NOGA-guided transendocardial injections.
- To determine the optimal cell type for improving cardiac function post-MI.
Main Methods:
- Nineteen pigs with chronic MI were allocated into placebo, MSC, or BMMNC groups.
- Repetitive NOGA-guided transendocardial injections were administered.
- Ejection fraction (EF) was measured at 4 and 8 weeks post-treatment.
Main Results:
- MSC injection significantly improved ejection fraction (EF) at 4 weeks post-MI.
- BMMNC injection did not yield significant improvements in EF at 4 weeks.
- No significant difference in EF was observed between cell-treated groups at 8 weeks, highlighting MSCs' sustained systolic effect.
Conclusions:
- Mesenchymal stem cells (MSC) demonstrate superior efficacy over bone marrow-derived mononuclear cells (BMMNC) in improving systolic function after chronic myocardial infarction.
- MSC therapy holds promise for cardiac repair in patients with chronic MI.
- NOGA-guided delivery facilitates cell transplantation for cardiac regeneration.
Abstract:
Cardiac cell therapy is a strategy to treat patients with chronic myocardial infarction (MI). No consensus exists regarding the optimal cell type. First, a comparison between autologous bone marrow-derived mononuclear cells (BMMNC) and mesenchymal stem cells (MSC) on therapeutic efficacy after MI was performed. Next, the effect of repetitive, NOGA-guided transendocardial injection was determined via a crossover design. Nineteen pigs were allocated in three groups: (1) placebo (at 4 and 8 weeks), (2) MSC (followed by placebo at 8 weeks), or (3) BMMNC (followed by MSC at 8 weeks) delivery including a priming strategy to enhance MSC effect. At 4 weeks, ejection fraction (EF) was significantly improved after MSC injection and not by BMMNC injection. After 8 weeks, no difference was observed in EF between cell-treated groups demonstrating the positive systolic effect of MSC. This study showed that MSC rather than BMMNC injection improves systolic function in chronic MI.
